Skip to main content
The Journal of Immunology Author Choice logoLink to The Journal of Immunology Author Choice
. 2026 Nov 16;215(11):vkag300. doi: 10.1093/jimmun/vkag300

Caspase-9 drives doxorubicin-induced inflammatory cell death, PANoptosis

R K Subbarao Malireddi 1,**, Bhesh Raj Sharma 2,**, Sangappa B Chadchan 3, Wen Chen 4, Rebecca E Tweedell 5, Thirumala-Devi Kanneganti 6,✉
PMCID: PMC13773039  PMID: 43038175

Abstract

The anthracycline chemotherapeutic drug doxorubicin and the well-known compound staurosporine (STS) have long been regarded as prototypical inducers of the nonlytic cell death pathway apoptosis, with doxorubicin serving as a standard experimental tool for studying caspase-9–dependent intrinsic apoptosis. We recently showed that STS induces PANoptosis, a distinct lytic cell death pathway initiated by innate immune sensors and driven by caspases and/or RIPKs through PANoptosome complexes. Here, we asked whether doxorubicin similarly induces lytic cell death. Using CRISPR-Cas9 technology, we developed caspase-9–deficient immortalized bone marrow–derived macrophages to circumvent the embryonic lethality associated with germline deletion of caspase-9. We found that doxorubicin induced dose- and time-dependent lytic cell death—PANoptosis—in a caspase-9–dependent manner. Together with our previous findings on STS and caspase-8, these data demonstrate that classical inducers of nonlytic apoptosis also drive lytic, inflammatory cell death (PANoptosis) in innate immune cells, specifically macrophages. We further show that caspase-9 is a key driver of PANoptosis in response to doxorubicin and is required for the activation of caspase-1, caspase-8, caspase-3/-7, and gasdermin E, which are hallmarks of PANoptosis. These findings establish a role for caspase-9 beyond canonical apoptosis and suggest that PANoptosis and the downstream inflammatory response may contribute to the biological effects previously attributed to apoptosis for doxorubicin as a chemotherapeutic agent and for caspase-9 in other cancer and inflammatory disease settings.

Keywords: caspase, innate immunity, inflammation, PANoptosis, PANoptosome

Introduction

PANoptosis is a distinct, innate immune, lytic cell death pathway initiated by innate immune sensors and driven by caspases and RIPKs through PANoptosome complexes.1–7 Several PANoptosomes have been defined downstream of innate immune sensors, including the ZBP1-, AIM2-, NLRP3-, RIPK1-, and NLRP12/NLRC5-PANoptosomes; deletion of the upstream innate sensor blocks PANoptotosome activation.8 PANoptosis persists in the absence of individual components such as caspase-1 or RIPK3, genetically and biochemically distinguishing it from other lytic cell death pathways such as pyroptosis and necroptosis.9

In PANoptosis, membrane permeabilization and the release of damage-associated molecule patterns (DAMPs) and cytokines are associated with inflammation. In contrast to PANoptosis, apoptosis drives nonlytic cell death, and it is immunologically silent under homeostatic conditions. Caspase-9 is the canonical initiator of the intrinsic apoptotic pathway. In response to cellular stress, BCL-2 family proteins regulate mitochondrial outer membrane permeabilization (MOMP), leading to cytochrome c release and formation of the APAF1 apoptosome, which activates caspase-9.10,26 Activated caspase-9 subsequently cleaves caspase-3 and caspase-7 to execute nonlytic apoptosis. Germline deletion of Casp9 in mice causes embryonic lethality due to neurodevelopmental defects,11,12 limiting studies of caspase-9 to primarily developmental contexts and leaving its role in postnatal innate immunity poorly understood.

Staurosporine (STS) and doxorubicin are widely used prototypical inducers of apoptosis.13,14 They have served as standard experimental tools for studying this pathway for decades. However, we recently demonstrated that STS induces PANoptosis in a dose-dependent manner and that this induction depends on caspase-8 and RIPK3.15 Given that doxorubicin and STS engage the same upstream mitochondrial pathway,16–19 we sought to determine whether doxorubicin similarly induces lytic inflammatory cell death. Because doxorubicin is a chemotherapeutic agent, understanding whether nonlytic or lytic cell death is induced and the potential immunogenicity of this cell death are critical to inform clinical applications. Using caspase-9–deficient immortalized bone marrow–derived macrophages (iBMDMs) to circumvent the embryonic lethality associated with germline Casp9 deletion, we found that doxorubicin induced dose- and time-dependent PANoptosis through caspase-9. In this pathway, caspase-9 controlled the coordinated activation of caspase-8, caspase-3/-7, and gasdermin E (GSDME). These findings identify caspase-9 as an upstream regulator of PANoptosis and suggest MOMP as a PANoptotic trigger.

Together with our findings on STS, these data fundamentally redefine the cell death outcomes induced by canonical intrinsic apoptotic stimuli and provide a mechanistic framework linking anthracycline-induced cell death to inflammatory signaling and DAMP release. This previously unknown role for PANoptosis, in contexts where nonlytic apoptosis has historically been observed, has critical implications for the inflammatory and immunogenic consequences of doxorubicin treatment, suggesting key considerations for therapeutic strategies.

Materials and methods

Mice

The Cas9 knockin mice (Rosa26-Cas9 knockin; The Jackson Laboratory, 028555)20 used in this study were maintained under specific pathogen–free conditions and bred at St. Jude Children’s Research Hospital’s Animal Resources Center. Mice were fed standard chow and maintained under a 12 h light-dark cycle. Animal studies were conducted using the standard protocols approved by the St. Jude Children’s Research Hospital Committee on the Use and Care of Animals.

Cas9-iBMDM culture and experiments

As described previously, the Cas9-expressing iBMDMs were electroporated21 with 2 guide RNAs (gRNAs) targeting Casp9 (Casp9-gRNA1: GGTCTCGGCGGGATCAGGCC; and Casp9-gRNA2: TCACAGACCTTGAGACCCGA); the resulting pools of cells are referred to as Casp9KO1 and Casp9KO2. The matching controls in which Casp9 was not deleted in Cas9-expressing iBMDMs were prepared in parallel by transfection without any gRNA and were named Casp9WT1 (wild-type [WT] 1) and Casp9WT2 (WT 2). The same Cas9-expressing mouse was used to generate all 4 iBMDM lines.

The gRNA-electroporated cells were allowed to rest for 5 d to achieve CRISPR-based deletion of the targeted gene. The cells were then expanded and seeded in 12- or 24-well plates at a seeding density of 1 × 106 cells/well and 0.5 × 106 cells/well, respectively, in complete DMEM (11995–065, Gibco) supplemented with 10% heat-inactivated FBS (HI-FBS; S1620, Biowest) and 1% penicillin-streptomycin (15070-063, Thermo Fisher Scientific) and rested for approximately 24 h before the experiments. The cells were then washed with PBS and treated with indicated concentrations of doxorubicin (15007, Cayman Chemical) in complete DMEM and used for IncuCyte imaging or were incubated for the indicated times before collecting samples for downstream analyses.

THP-1 macrophage differentiation

The immortalized human monocytic THP-1 cells (TIB-202, ATCC) were cultured in RPMI medium (10-040-CV, Corning) containing 10% HI-FBS and 1% penicillin and streptomycin. For experiments, cells were seeded at 0.8 × 106 cells/well in 24-well plates in RPMI medium containing 10% HI-FBS and 1% penicillin and streptomycin and treated with 125 ng/mL PMA (P1585, Sigma) for 24 h to differentiate into macrophages.

Real-time cell death analysis

The kinetics of cell death were monitored using the IncuCyte S3 or SX5 (Sartorius) live-cell analysis system. iBMDMs or THP-1 differentiated macrophages were seeded and treated with vehicle (endotoxin-free water) or the indicated doses of doxorubicin. Doxorubicin (or vehicle) remained in the medium throughout the experiment. Cell death was measured by propidium iodide (PI) (P3566, Life Technologies) or Incucyte Cytotox NIR Dye (Sytox or SytoxDeepRed [SytoxDR]; 4846, Sartorius) incorporation, per the manufacturer’s protocol. Fluorescence and phase-contrast images were acquired in real time every 1 h. PI- and Sytox-positive dead cells were marked with a red mask and quantified using the software package supplied with the IncuCyte imager. To calculate the percentage of cell death, the ratio of dead cells to total cells was multiplied by 100. To calculate this ratio in THP-1 cells, the number of PI-positive cells was divided by the number of cells that were seeded in the well. To calculate this ratio in iBMDMs, due to the rate of cellular division, the number of Sytox-positive cells was divided by the number of Sytox-positive cells in an analogous well (seeded at the same time with the same number of cells) treated with 70% ethanol for 10 min to induce 100% cell lysis. A minimum of 4 images/well were captured for the analysis of each time point. In some cases, a single WT was used to compare with multiple knockout (KO) lines seeded and stimulated at the same time in the same experiment, and a single vehicle-treated control was used to compare across multiple doxorubicin doses. The data are plotted separately in the figures for optimal visualization; therefore, the same WT data appear in multiple panels between Figs. 1B and 2B.

Figure 1.

Microscopy images and membrane impermeant dye uptake quantification curves showing increasing cell death over time in response to doxorubicin in WT iBMDMs and in THP-1 cells. The effect is dose-dependent.

Doxorubicin induces lytic cell death in a dose- and time-dependent manner. (A, B) Representative images at 0, 3, 6, and 12 h after treatment (A) and quantification of lytic cell death (B) in 2 replicates of WT iBMDMs from Cas9-expressing BMDMs (WT 1 and WT 2) treated with vehicle or the indicated concentrations of doxorubicin (Dox). SytoxDeepRed (SytoxDR) was used as the real-time marker of lytic cell death. Vehicle and Dox 2.5–20 μM dosing was performed on a single plate, and the 40-μM dose was performed on a separate plate run at the same time from the same parental pool of cells. Scale bar, 50 µm. (C, D) Representative images at 0, 12, and 20 h after treatment (C) and quantification of lytic cell death (D) in human THP-1 macrophages treated with vehicle or the indicated concentrations of Dox. PI (red) was used as the real-time marker of lytic cell death. Scale bar, 50 µm. Data are representative of at least 3 independent experiments (A–D) and are presented as mean ± SEM (B, D).

Figure 2.

Microscopy images and membrane impermeant dye uptake quantification curves showing increasing cell death over time in WT iBMDMs at 5 different doxorubicin dose levels, but minimal cell death in Casp9 KO iBMDMs.

Caspase-9 drives doxorubicin-induced lytic cell death. (A, B) Representative images at 0, 3, 6, and 12 h after treatment (A) and quantification of lytic cell death (B) in caspase-9–deficient iBMDMs (Casp9KO1 and Casp9KO2 iBMDMs) and matched caspase-9–sufficient iBMDMs (Casp9WT1 and Casp9WT2) treated with vehicle or the indicated concentrations of doxorubicin (Dox). SytoxDeepRed (SytoxDR) was used as the real-time marker of lytic cell death. Scale bar, 50 µm. Data are representative of at least 3 independent experiments (A, B) and are presented as mean ± SEM (B). Two-way ANOVA with Tukey’s multiple comparisons test was used to determine statistical significance. ****P < 0.0001, comparing each KO with the WT. In some cases, a single WT was used to compare with multiple KO lines seeded and stimulated at the same time in the same experiment. The data are plotted separately in the figures for optimal visualization; therefore, the same WT appears in Figs. 1B and 2B. Vehicle and Dox 2.5- to 20-μM dosing was performed on a single plate, and the 40-μM dose was performed on a separate plate run at the same time from the same parental pool of cells.

Caspase-3/7 activation staining

Caspase-3/7 activation was imaged using IncuCyte Caspase-3/7 Green Dye (4440, Sartorius) according to the manufacturer’s instructions. Briefly, the cells were treated with vehicle or 20 μM doxorubicin for 3 or 6 h, then were washed once with warm Dulbecco’s PBS, removing doxorubicin; then fresh complete DMEM medium containing caspase-3/7 dye, without doxorubicin, was added. The plates were scanned by IncuCyte imaging 30 min later, with fluorescence and phase-contrast images acquired. Caspase-3/7-positive cells were marked with a green color mask.

Immunoblotting analysis

As described previously,21 to blot for caspases, Cas9-iBMDMs were lysed along with the supernatant using 125 μL of 4× SDS loading buffer containing 50 μL of caspase lysis buffer (1× protease inhibitors, 1× phosphatase inhibitors, 10% NP-40, and 25 mM DTT). To detect other proteins in the cell lysates alone, the supernatants were aspirated, and the cells were lysed using RIPA buffer. To probe for secreted DAMPs, supernatants were collected, cleared by centrifugation for 5 min at 5,000 g, then combined with appropriate amount of 4× SDS loading buffer. All samples were boiled at 100 °C for 10 min prior to loading onto gels. The samples were separated on 10% to 12% polyacrylamide gels and then transferred onto polyvinylidene difluoride membranes. After blocking the membranes with 5% skim milk for 1 h at room temperature, the blots were incubated with their respective primary Abs overnight at 4 °C. Subsequently, the blots were washed with 1× TBST and incubated with secondary Abs conjugated with HRP for 1 h at room temperature. Immunoblot images were acquired on an Amersham Imager using Immobilon Forte Western HRP Substrate (WBLUF0500, Millipore) or SuperSignal West Femto Maximum Sensitivity Substrate (34096, Thermo Fisher Scientific). In certain cases, the immunoblots were stripped using stripping buffer (Restore Western Blot Stripping Buffer; 21059, Thermo Fisher Scientific) and reprobed for a different protein of interest. Specifically, the caspase-3 immunoblot was stripped and reprobed for β-actin. The following Abs were used: anti–caspase-1 (AG-20B-0042, AdipoGen; 1:1,000), anti–caspase-3 (9662, Cell Signaling Technology [CST]; 1:1,000), anti-cleaved caspase-3 (9661, CST; 1:1,000), anti–caspase-8 (4927, CST; 1:1,000), anti-cleaved caspase-8 (8592; CST, 1:1,000), anti–caspase-9 (9504, CST; 1:1,000), anti-GSDMD (ab209845, Abcam; 1:1,000), anti-GSDME (ab215191, Abcam; 1:1,000), anti-HMGB1 (ab18256, Abcam; 1:1,000), anti-LDHA (19987-1-AP, Proteintech; 1:1,000), anti–β-actin (66009-1-IG, Proteintech; 1:5,000), and HRP-conjugated secondary Abs (anti-rabbit [111-035-047] and anti-mouse [315-035-047]; Jackson ImmunoResearch Laboratories, 1:5,000).

Statistical analysis

GraphPad Prism version 10 was used for data analysis. Data are shown as mean ± SEM. Statistical significance was determined using 2-way ANOVA analysis, with Tukey’s multiple comparisons test. The number of experimental replicates is indicated in the corresponding figure legends. P values less than 0.05 were considered statistically significant; P values are given in figures and/or their captions, where applicable.

Results

Doxorubicin induces lytic cell death in a dose- and time-dependent manner

Our recent studies demonstrated that STS, a canonical inducer of MOMP-dependent intrinsic apoptosis, drives PANoptosis.15 Given that doxorubicin engages the same upstream MOMP pathway,16–18 we asked whether doxorubicin similarly induces lytic cell death. WT iBMDMs were treated with increasing concentrations of doxorubicin (2.5–40 µM) and monitored in real time using Sytox, a membrane-impermeant dye that stains cells with disrupted plasma membranes, indicating lytic cell death. Doxorubicin induced dose- and time-dependent Sytox uptake beginning within 3 to 6 h and reaching maximal levels by 12 h (Fig. 1A, B). Two independent WT lines showed comparable responses across all concentrations tested. Additionally, we observed dose- and time-dependent lytic cell death in THP-1 macrophages in response to doxorubicin treatment, as measured by uptake of PI (Fig. 1C, D). Collectively, these data suggest that doxorubicin drives robust lytic cell death in both murine and human macrophages.

Caspase-9 regulates the doxorubicin-induced lytic cell death

Given the known role of caspase-9 in response to doxorubicin, we assessed whether caspase-9 was involved in driving doxorubicin-induced lytic cell death. To do this, we used CRISPR/Cas9 technology to generate 2 separate caspase-9–deficient iBMDM cell lines (Casp9KO1 and Casp9KO2), thereby circumventing the embryonic lethality associated with germline Casp9 deletion. Both Casp9KO iBMDM lines were markedly protected from lytic cell death, whereas matched WT iBMDMs (Casp9WT1 and Casp9WT2) showed robust dose-dependent Sytox uptake across all concentrations tested (Fig. 2A, B). Protection was consistent across both the caspase-9–deficient lines, establishing caspase-9 as a critical upstream regulator of doxorubicin-induced lytic cell death.

Doxorubicin-induced PANoptosis is mediated by the caspase-9 axis

To define the downstream effectors activated by caspase-9 in response to doxorubicin, we compared the biochemical activation of cell death molecules in WT and Casp9KO iBMDMs (Fig. 3A). The absence of caspase-9 protein in Casp9KO iBMDMs confirmed efficient deletion in these cells (Fig. 3A). In WT cells (Casp9WT), doxorubicin induced cleavage of caspase-1 (from pro-caspase-1, P45, to the active caspase-1, P20), caspase-8 (P55 to P43/P18), caspase-3 (P35 to P19/P17), gasdermin D (GSDMD) (P53 to the inactive form of GSDMD, P20), and GSDME (P53 to the active form of GSDME, P34) (Fig. 3A). Notably, these effectors were all activated at similar time points, which is a kinetic hallmark of PANoptosis rather than sequential activation of other pathways (Fig. 3A). Additionally, WT cells released the DAMPs lactate dehydrogenase (LDH) and HMGB1 into culture supernatants (Fig. 3A). In contrast, Casp9KO iBMDMs showed markedly reduced or absent cleavage of caspase-1, caspase-8, caspase-3, GSDMD, and GSDME. Consistent with these findings, LDH/HMGB1 release was substantially decreased in Casp9KO iBMDMs (Fig. 3A). These results indicate that caspase-9 regulates the activation of cell-death molecules and DAMP release.

Figure 3.

In panel A, western blot images show activation of PANoptosis markers in doxorubicin-treated WT iBMDMs, but not in Casp9 KO iBMDMs. In B, microscopy images show cells containing activated CASP3/7 in doxorubicin-treated WT iBMDMs but not in vehicle-treated or Casp9 KO iBMDMs.

Doxorubicin-induced PANoptosis is biochemically mediated by caspase-9. (A) Immunoblot analysis of caspase-9–deficient iBMDMs (Casp9KO1 and Casp9KO2 iBMDMs) and matched caspase-9–sufficient iBMDMs (Casp9WT1 and Casp9WT2) treated with vehicle, 20 μM doxorubicin (Dox), or 40 μM Dox for 20 h. Immunoblots for caspase-9 (CASP9; P49); pro-caspase-1 (P45) and cleaved caspase-1 (P20) (CASP1); pro-caspase-8 (P55) and cleaved caspase-8 (P43/P18) (CASP8); pro-caspase-3 (P35) and cleaved caspase-3 (P19/P17) (CASP3); pro-GSDMD (P53), active GSDMD (P30), and inactive GSDMD (P20); pro-GSDME (P53) and cleaved GSDME (P34), as well as LDHA (P37) and HMGB1 (P29) release into the supernatant (Sup) are shown. β-Actin was used as a loading control. The asterisk indicates a nonspecific band. (B) Caspase-3/7 activation (green) in Casp9WT1 and Casp9KO1 iBMDMs at 3.5 h and 6.5 h after treatment with vehicle or 20 µM Dox. Scale bar, 50 µm. Data are representative of at least 3 independent experiments (A, B).

To further assess the timing of caspase-9–induced effector activation, we assessed the activation of caspase-3/7 in WT and Casp9KO iBMDMs. Caspase-3/7 activation occurred early, appearing by 3.5 h after treatment, when cell death did not begin until ∼6 h after treatment with the 20 μM dose of doxorubicin. Furthermore, caspase-3/7 activation was markedly reduced in Casp9KO iBMDMs relative to WT controls at matched time points (Fig. 3B), demonstrating that caspase-9 is required for both plasma membrane disruption and for downstream executioner caspase activation in response to doxorubicin. Combined with the biochemical activation pattern (Fig. 3A), these results suggest that doxorubicin induces caspase-9–dependent PANoptosis.

Discussion

Doxorubicin has been used for decades as a therapeutic agent to induce caspase-9–dependent intrinsic apoptosis,13,14 leading to cell death that is nonlytic and immunologically silent. Furthermore, doxorubicin is a potent chemotherapeutic agent that is approved by the US Food and Drug Administration for the treatment of acute lymphoblastic leukemia, acute myeloblastic leukemia, Hodgkin lymphoma, and non-Hodgkin lymphoma, as well as metastatic cases of breast cancer, Wilms’ tumor, neuroblastoma, soft tissue sarcoma, bone sarcomas, ovarian carcinoma, transitional cell bladder carcinoma, thyroid carcinoma, gastric carcinoma, and bronchogenic carcinoma. Given its role in chemotherapy, understanding whether doxorubicin induces lytic or nonlytic cell death is critical, because lytic cell death can release cytokines and DAMPs that further drive paracrine PANoptosis; these processes improve immunogenicity but also drive inflammatory signaling. Our findings show that doxorubicin can induce dose-dependent PANoptosis and that caspase-9 functions as an upstream regulator of this response. Together with our previous finding that STS also induces PANoptosis in a caspase-8/RIPK3–dependent manner,15 these data suggest that MOMP may trigger PANoptosis.

The Casp9KO iBMDM system generated here overcomes the long-standing limitation imposed by embryonic lethality in germline Casp9-deficient mice and enables direct interrogation of caspase-9 function in innate immune signaling. Mechanistically, our data place caspase-9 upstream of caspase-8, caspase-3/7, and GSDME activation in a lytic inflammatory pathway. This contrasts with its established role in the APAF1 apoptosome, where caspase-9 functions primarily as an initiator of nonlytic apoptosis through activation of only caspase-3 and caspase-7.22–24 Caspase-8 is a central component of PANoptosomes characterized to date, and its activation downstream of caspase-9 in this context, along with the activation of additional molecular markers of PANoptosis, supports the conclusion that doxorubicin engages a PANoptotic signaling program rather than classical apoptosis at this dose.

Anthracyclines are among the most immunostimulatory chemotherapeutic agents in clinical use and show strong synergy with immune checkpoint blockade.25–27 Classical nonlytic apoptosis is generally associated with membrane integrity and limited inflammatory signaling, making it unlikely that apoptosis could account for these immunological effects. In contrast, PANoptosis is intrinsically lytic and promotes the release of DAMPs and inflammatory mediators.8 The observed caspase-9–dependent release of LDH and HMGB1 therefore provides a mechanistic link for the immunogenic properties of doxorubicin and suggests that PANoptosis contributes to anthracycline-driven immune priming. These findings also have implications for therapeutic resistance. Tumors resistant to apoptosis through loss of downstream apoptotic effectors may still retain susceptibility to PANoptotic execution pathways involving GSDME or other lytic mediators.

Together with our prior findings on STS, these data establish that canonical intrinsic apoptotic stimuli can drive PANoptosis, showing that mitochondrial stress interfaces with innate immune inflammatory cell death signaling. Furthermore, these findings establish that doxorubicin acts through caspase-9 specifically to drive PANoptosis. Therefore, the inflammatory and immunogenic consequences of doxorubicin treatment, including DAMP release, induction of paracrine PANoptosis, and immune activation, should be considered in the context of PANoptosis in addition to nonlytic apoptosis. These findings redefine the cell death consequence of these prototypical triggers and suggest key considerations for therapeutic strategies.

Acknowledgments

The authors thank all the members of the Kanneganti laboratory for their comments and suggestions during the development of this manuscript. They thank K. Combs for mouse colony support and Kristine Zengeler, PhD, and Peter Gorsuch, PhD, for scientific editing support.

Contributor Information

R K Subbarao Malireddi, Department of Immunology, St. Jude Children’s Research Hospital, Memphis, TN, United States.

Bhesh Raj Sharma, Department of Immunology, St. Jude Children’s Research Hospital, Memphis, TN, United States.

Sangappa B Chadchan, Department of Immunology, St. Jude Children’s Research Hospital, Memphis, TN, United States.

Wen Chen, Department of Immunology, St. Jude Children’s Research Hospital, Memphis, TN, United States.

Rebecca E Tweedell, Department of Immunology, St. Jude Children’s Research Hospital, Memphis, TN, United States.

Thirumala-Devi Kanneganti, Department of Immunology, St. Jude Children’s Research Hospital, Memphis, TN, United States.

Author contributions

R.K. Subbarao Malireddi (Conceptualization [Equal], Investigation [Equal], Methodology [Lead], Formal analysis [Equal], Writing—original draft [Equal], Writing—review & editing [Equal]), Bhesh Raj Sharma (Conceptualization [Supporting], Investigation [Equal], Methodology [Supporting], Formal analysis [Equal], Writing—review & editing [Supporting]), Sangappa B. Chadchan (Investigation [Supporting], Formal analysis [Supporting], Validation [Supporting], Writing—review & editing [Supporting]), Wen Chen (Investigation [Supporting], Formal analysis [Supporting]), Rebecca E. Tweedell (Formal analysis [Supporting], Writing—original draft [Equal], Writing—review & editing [Equal]), and Thirumala-Devi Kanneganti (Conceptualization [Equal], Supervision [Lead], Funding acquisition [Lead], Writing—review & editing [Supporting])

Funding

This work was supported in part by the US National Institutes of Health (grants AI101935, AI124346, AI160179, and CA253095 to T.-D.K.) and the American Lebanese Syrian Associated Charities (to T.-D.K.). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

Conflicts of interest

None declared.

Data availability

All data are contained within the manuscript. Any additional information is available from the lead contact upon reasonable request.

References

  • 1. Christgen S  et al.  Identification of the PANoptosome: A molecular platform triggering pyroptosis, apoptosis, and necroptosis (PANoptosis). Front Cell Infect Microbiol. 2020;10:237. 10.3389/fcimb.2020.00237 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2. Lee S  et al.  AIM2 forms a complex with pyrin and ZBP1 to drive PANoptosis and host defence. Nature. 2021;597:415–419. 10.1038/s41586-021-03875-8 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3. Malireddi RKS  et al.  RIPK1 distinctly regulates Yersinia-induced inflammatory cell death, PANoptosis. Immunohorizons. 2020;4:789–796. 10.4049/immunohorizons.2000097 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4. Sharma BR, Choudhury SM, Abdelaal HM, Wang Y, Kanneganti TD.  Innate immune sensor NLRP3 drives PANoptosome formation and PANoptosis. J Immunol. 2025;214:1236–1246. 10.1093/jimmun/vkaf042 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5. Sundaram B  et al.  NLRC5 senses NAD(+) depletion, forming a PANoptosome and driving PANoptosis and inflammation. Cell. 2024;187:4061–4077.e4017. 10.1016/j.cell.2024.05.034 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6. Sundaram B  et al.  NLRP12-PANoptosome activates PANoptosis and pathology in response to heme and PAMPs. Cell. 2023;186:2783–2801.e2720. 10.1016/j.cell.2023.05.005 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7. Zheng M, Karki R, Vogel P, Kanneganti TD.  Caspase-6 is a key regulator of innate immunity, inflammasome activation, and host defense. Cell. 2020;181:674–687.e613. 10.1016/j.cell.2020.03.040 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8. Pandeya A, Kanneganti TD.  Therapeutic potential of PANoptosis: innate sensors, inflammasomes, and RIPKs in PANoptosomes. Trends Mol Med. 2024;30:74–88. 10.1016/j.molmed.2023.10.001 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9. Pandian N, Kanneganti TD.  PANoptosis: a unique innate immune inflammatory cell death modality. J Immunol. 2022;209:1625–1633. 10.4049/jimmunol.2200508 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10. Malireddi RKS, Kanneganti TD.  Three decades of caspases and RIPKs in life and death. Hum Mol Genet. 2025;34:R121–R136. 10.1093/hmg/ddaf106 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11. Hakem R  et al.  Differential requirement for caspase 9 in apoptotic pathways in vivo. Cell. 1998;94:339–352. 10.1016/s0092-8674(00)81477-4 [DOI] [PubMed] [Google Scholar]
  • 12. Kuida K  et al.  Reduced apoptosis and cytochrome c-mediated caspase activation in mice lacking caspase 9. Cell. 1998;94:325–337. 10.1016/s0092-8674(00)81476-2 [DOI] [PubMed] [Google Scholar]
  • 13. Jung K, Reszka R.  Mitochondria as subcellular targets for clinically useful anthracyclines. Adv Drug Deliv Rev. 2001;49:87–105. 10.1016/s0169-409x(01)00128-4 [DOI] [PubMed] [Google Scholar]
  • 14. Kaufmann SH, Earnshaw WC.  Induction of apoptosis by cancer chemotherapy. Exp Cell Res. 2000;256:42–49. 10.1006/excr.2000.4838 [DOI] [PubMed] [Google Scholar]
  • 15. Sarkar R, Choudhury SM, Kanneganti TD.  Classical apoptotic stimulus, staurosporine, induces lytic inflammatory cell death, PANoptosis. J Biol Chem. 2024;300:107676. 10.1016/j.jbc.2024.107676 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16. Childs AC, Phaneuf SL, Dirks AJ, Phillips T, Leeuwenburgh C.  Doxorubicin treatment in vivo causes cytochrome C release and cardiomyocyte apoptosis, as well as increased mitochondrial efficiency, superoxide dismutase activity, and Bcl-2:Bax ratio. Cancer Res. 2002;62:4592–4598. [PubMed] [Google Scholar]
  • 17. Kalkavan H, Green DR.  MOMP, cell suicide as a BCL-2 family business. Cell Death Differ. 2018;25:46–55. 10.1038/cdd.2017.179 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18. Wallace KB, Sardao VA, Oliveira PJ.  Mitochondrial determinants of doxorubicin-induced cardiomyopathy. Circ Res. 2020;126:926–941. 10.1161/CIRCRESAHA.119.314681 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19. Yang ES, Huh YJ, Park J-W. RNA interference targeting sensitive-toapoptosis gene potentiates doxorubicin- and staurosporine-induced apoptosis of PC3 cells. Anticancer Res. 2013;33:847–855. [PubMed] [Google Scholar]
  • 20. Chu VT  et al.  Efficient generation of Rosa26 knock-in mice using CRISPR/Cas9 in C57BL/6 zygotes. BMC Biotechnol. 2016;16:4. 10.1186/s12896-016-0234-4 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21. Malireddi RKS, Kanneganti TD.  Chromatin regulator SMARCA4 is essential for MHV-induced inflammatory cell death, PANoptosis. Viruses. 2024;16:1261. 10.3390/v16081261 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22. Kerr JF, Wyllie AH, Currie AR.  Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. Br J Cancer. 1972;26:239–257. 10.1038/bjc.1972.33 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23. Vitale I  et al.  Apoptotic cell death in disease-current understanding of the NCCD 2023. Cell Death Differ. 2023;30:1097–1154. 10.1038/s41418-023-01153-w [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24. Blake SJ  et al.  Suppression of metastases using a new lymphocyte checkpoint target for cancer immunotherapy. Cancer Discov. 2016;6:446–459. 10.1158/2159-8290.CD-15-0944 [DOI] [PubMed] [Google Scholar]
  • 25. Chao Y  et al.  Localized cocktail chemoimmunotherapy after in situ gelation to trigger robust systemic antitumor immune responses. Sci Adv. 2020;6:eaaz4204. 10.1126/sciadv.aaz4204 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26. Brentnall M, Rodriguez-Menocal L, De Guevara RL, Cepero E, Boise LH.  Caspase-9, caspase-3 and caspase-7 have distinct roles during intrinsic apoptosis. BMC Cell Biol. 2013;14:32. 10.1186/1471-2121-14-32 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27. Rios-Doria J  et al.  Doxil synergizes with cancer immunotherapies to enhance antitumor responses in syngeneic mouse models. Neoplasia. 2015;17:661–670. 10.1016/j.neo.2015.08.004 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28. Singh R, Letai A, Sarosiek K.  Regulation of apoptosis in health and disease: the balancing act of BCL-2 family proteins. Nat Rev Mol Cell Biol. 2019;20:175–193. 10.1038/s41580-018-0089-8 [DOI] [PMC free article] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Data Availability Statement

All data are contained within the manuscript. Any additional information is available from the lead contact upon reasonable request.


Articles from The Journal of Immunology Author Choice are provided here courtesy of Oxford University Press

RESOURCES